Simposi
Innovation Of Mechanism Of Action In Oncology
26 ottobre 2017 / 15.00-16.00
| 172 |
NSCLC: Mechanism of Action of ALK inhibitors and 2nd generation Immunotherapies Romano Danesi (Pisa) |
| 173 |
NSCLC updates on ALK inhibitors and 2nd generation immunotherapies clinical data Federico Cappuzzo (Ravenna) |